Beyond 30:
Why the industry standard sample size in
pharmaceutical qualitative research is
leaving insights on the table.

By DOCREPLAY.ai

ABSTRACT

For decades, pharmaceutical qualitative research has operated on a near-universal assumption: 30 respondents is enough. This number became the default not because it was proven optimal, but because it was the practical ceiling of what human-led research could manage. Within that ceiling, a secondary assumption took hold – that insights converge around respondent 16, and that everything after that is repetition. Both assumptions went largely unchallenged because no one had ever systematically gone beyond them. AI-powered voice capture technology has changed that. When sample sizes reach 60, 70, or more respondents, a different picture emerges. The first 30 deliver anecdotes and directional patterns. The respondents beyond 30 deliver the full map: a statistically grounded, comprehensive view of what physicians, patients, and caregivers actually know, believe, feel, and do. This white paper makes the case that 30 was never the right answer. It was simply the only answer available at the time.

WHERE THE NUMBER 30 CAME FROM

The 30-respondent standard in pharmaceutical qualitative research was not born from a rigorous statistical analysis of what sample size produces optimal insight. It emerged from a practical constraint: human moderators conducting 60-minute depth interviews can realistically manage a limited number of respondents within the timelines and budgets available to brand teams. Thirty became the industry norm because it was achievable, not because it was ideal.

A 30-respondent sample in qualitative research delivers approximately a 70% confidence interval. For exploratory studies where direction is the goal, this is often sufficient. But for strategic decisions involving creative assets, message hierarchy, prescribing logic, or positioning, a 70% confidence interval means that nearly one in three relevant perspectives is likely missing from the analysis. Brand teams have been making high-stakes decisions on incomplete data not because they chose to, but because the
methodology never offered them anything more.

THE CONVERGENCE MYTH

Any experienced qualitative researcher recognizes the feeling: somewhere around respondent 16, the themes begin to repeat. The same concerns surface. The same language appears. The moderator begins to anticipate what the next respondent will say before they say it. This phenomenon, often called thematic saturation, became a foundational belief in pharmaceutical qualitative research. If insights converge at 16, the thinking goes, then respondents 17 through 30 are largely confirmatory, and anything beyond 30 is redundant.

The problem is that this assumption was never tested beyond 30. Researchers felt saturation because they stopped at a point where saturation seemed plausible. No one had the tools to systematically field 60 or 70 qualitative interviews, quantify every verbatim response, and examine what patterns existed in the respondents beyond the traditional cutoff. The convergence belief was not validated evidence. It was a false ceiling.

WHAT HAPPENS AFTER RESPONDENT 30

AI-powered voice capture technology has made it possible, for the first time, to field qualitative studies at sample sizes of 68 respondents and beyond, within 20 days and at a cost that makes it operationally viable. What these larger studies are revealing challenges the convergence assumption in a
fundamental way.

The first 30 respondents do produce directional themes. But they produce them as anecdotes, quotes, and patterns that feel representative without being statistically so. The respondents beyond 30 do something different. They transform anecdote into evidence. They reveal the full distribution of perspectives across a physician or patient population, including the minority viewpoints that a 30-respondent study will miss entirely. They surface the segments within the audience that behave or believe differently from the majority, and that may represent the most strategically important opportunities for the brand.

A study of 68 or more respondents, with every verbatim captured and quantified, delivers something closer to a full map of customer understanding. Brand teams can see not just what themes are present, but how frequently each appears, what sentiment surrounds it, and how it varies across physician specialty, patient segment, or geographic market. This is the difference between knowing that prescribing hesitation exists and knowing exactly how many physicians experience it, in what context, and in what language they express it.

THE STANDARD WAS A CONSTRAINT, NOT A CONCLUSION

Pharmaceutical qualitative research has operated within the boundaries of what human-led methodology could deliver for 40 or 50 years. Those boundaries shaped assumptions that became doctrine. Thirty respondents is enough. Insights saturate at sixteen. Going further is unnecessary. These beliefs were reasonable given the tools available at the time. They are no longer reasonable when better tools exist.

Brand teams that continue to rely on 30-respondent studies for strategic decisions are not making a methodological choice. They are inheriting a constraint that no longer applies. The question is no longer whether it is possible to go beyond 30. It is whether the brand can afford not to.

About DOCREPLAY.ai

DOCREPLAY.ai delivers AI-powered strategic direction through voice intelligence for pharmaceutical
market research. When you have defined strategic questions requiring rapid decisive answers –
testing creative concepts, evaluating messaging, or answering business questions, DOCREPLAY.ai
delivers 68 physician or patient perspectives in 20 days with statistical rigor that drives confident
decisions